Intraductal Papillary Mucinous Neoplasm (IPMN): A Precursor to Pancreatic Cancer

Author(s): Albrecht Neesse , Patrick Michl , Marc Kalinowski , Peter J. Barth , Detlef K. Bartsch , Volker Ellenrieder , Thomas M. Gress .

Journal Name: Current Cancer Therapy Reviews

Volume 6 , Issue 3 , 2010

Become EABM
Become Reviewer


Cystic neoplasms of the pancreas account for about 10% of pancreatic tumors. Intraductal papillary mucinous neoplasms (IPMNs) are the most common cystic tumors of the pancreas presenting with no or unspecific clinical symptoms. Diagnosis of IPMNs is challenging and accomplished by CT, MRI, MRCP and EUS. Primarily, IPMNs are regarded as benign cystic lesions, however, almost 60% of resected IPMNs reveal malignant or invasive growth. The risk to progress to malignancy varies between 20-90% strongly depending on the origin of the lesion (main-duct type, branch-duct type) and clinico-pathological characteristics. Recently, first standardized algorithms for the treatment of IPMNs have been formulated, however, therapeutic consequences (surgical approach vs. surveillance strategy) are still controversial. This review provides a detailed overview of the currently discussed options for diagnostics, therapy and surveillance of IPMNs.

Keywords: IPMN, cystic lesions of the pancreas, precursor of pancreatic cancer, pancreatic cancer

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [175 - 184]
Pages: 10
DOI: 10.2174/157339410791698197
Price: $58

Article Metrics

PDF: 2